Gold rally may be losing steam but no major correction seen: DB
NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH), whose stock has surged over 175% year-to-date according to InvestingPro data, has filed multiple U.S. provisional patent applications for its lead topical therapeutic candidate HT-001, expanding its potential use to treat dermatological side effects associated with cancer treatments, according to a company press release.
The new patent applications cover the treatment of drug-induced hypersensitivity syndrome, radiotherapy-induced rash, and dermatological conditions associated with MENIN inhibitor therapy.
MENIN inhibitors represent an emerging class of targeted oncology drugs being developed for acute leukemias and certain solid tumors. While showing promising antitumor activity, these treatments often cause severe skin reactions that can lead to dose reductions or treatment discontinuation.
"These additional patent applications demonstrate our commitment to unlocking the full therapeutic potential of HT-001 across multiple high-value indications," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. The company maintains a strong financial position with a current ratio of 27.57 and minimal debt, according to InvestingPro data.
HT-001 is currently being developed as a topical treatment for chemotherapy-induced rash, particularly for patients receiving EGFR inhibitors and other targeted therapies. The expanded patent portfolio positions the drug as a potential solution for a broader range of treatment-related skin disorders.
The company’s topical formulation aims to address dermatological toxicities directly, potentially allowing patients to continue their cancer treatments without interruption or dose reduction.
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological and inflammatory conditions. The information in this article is based on a press release statement from the company.
In other recent news, Hoth Therapeutics has made significant advancements in its clinical and research initiatives. The company has submitted a Clinical Trial Application to the European Medicines Agency to extend its ongoing Phase II trial of HT-001, a topical treatment for skin toxicities related to Epidermal Growth Factor Receptor inhibitors, into European Union countries. Hoth has also started using Lantern Pharma’s PredictBBB.ai, an AI platform that predicts blood-brain barrier permeability, to enhance drug development processes. Additionally, the company announced promising preclinical results for its precision antisense candidate HT-KIT, which showed significant anti-tumor efficacy in preclinical models.
In corporate developments, Hoth Therapeutics has renewed CEO Robb Knie’s contract, securing his leadership for another three years with provisions for automatic renewals. The contract includes an annual base salary of $550,000 and the potential for an annual bonus of up to the same amount, contingent on performance targets. These recent developments reflect Hoth Therapeutics’ ongoing efforts to advance its research and strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.